KSCM
IOVA icon

Kamunting Street Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Kamunting Street Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,000
Closed -$210K – 48
2020
Q1 		$210K Buy
+7,000
New +$186K 0.4% 35

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Kamunting Street Capital Management's IOVA Position: Q2 2020 in Review

Kamunting Street Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2020, closing a stake of 7,000 shares — an estimated $210K sold.

Kamunting Street Capital Management first reported a position in IOVA in Q1 2020 and held it in 1 quarter. The position peaked at $210K in Q1 2020. 257 funds tracked by Wall St. Rank hold IOVA as of Q2 2020.

  • Kamunting Street Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • Kamunting Street Capital Management sold 7,000 Iovance Biotherapeutics shares in Q2 2020, an estimated $210K.
  • Kamunting Street Capital Management first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 1 quarter.
  • Kamunting Street Capital Management's Iovance Biotherapeutics position peaked at $210K in Q1 2020.
  • 257 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2020.

Based on Kamunting Street Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.